Effect of early use of levosimendan versus placebo on top of a conventional strategy of inotrope use on a combined morbidity-mortality endpoint in patients with cardiogenic shock.LevoHeartShock - 2018/LEVOHEARTSHOCK

CHRU De Nancy0 个研究点目标入组 610 人开始时间: 2024年7月9日最近更新: 2024年8月21日

适应症

试验速览

暂无简介。

•Adult patient = 18 years with cardiogenic shock, Adequate intravascular volume, Norepinephrine to maintain MAP at least at 65 mmHg for at least 3 hours and less than 24h. At inclusion the dose must be <1 microgram/kg/min under norepinephrine base or <2 microgram/kg/min under norepinephrine tartrate, OR/AND Dobutamine since at least 3h and less than 24h and at dose = 5 microgram/kg/min at inclusion., Tissue hypoperfusion: at least 1 sign (lactate = 2 mmol/l; mottling, capillary refeel time > 3 seconds, oliguria <500ml/24h or = 20 ml/h during the last 2 hours, ScVO2 = 60% or veno-arterial PCO2 gap = 5 mmHg);, Patient affiliated to social security plan.

•Myocardial sideration after cardiac arrest of non-cardiac etiology;, No flow time higher > 3 minutes, Cardiac arrest with unknown no flow duration, Total duration of cardiac arrest (no flow plus low flow) > 45 minutes, Cerebral deficit with fixed dilated pupils, Patient moribund on the day of enrollment, Irreversible neurological pathology, Known hypersensitivity to levosimendan or placebo, or one of its excipients;, Pregnant woman, birthing or breastfeeding mother, Person deprived of liberty for judicial or administrative decision, Minor (not emancipated), Immediate or anticipated (within 6 hours) indication of ECLS;, Adult subject to a legal protection measure (such as guardianship, conservatorship), Use of VA-ECMO or IMPELLA or LVAD, Cardiogenic choc post cardiac surgery under cardiopulmonary bypass (CPBP) weaned for less or equal of 6 hours., Chronic renal failure requiring hemodialysis;, Cardiotoxic poisoning, Septic cardiomyopathy, Previous levosimendan administration within 15 days, Cardiac arrest with non-shockable rhythm

发起方

CHRU De Nancy